LEXINGTON, Mass., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the
development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced
that on January 1, 2017, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement
stock options to purchase a total of 185,000 shares of Curis common stock to eight new employees, with a grant date of January 1,
2017 (the “Q1 2017 Inducement Grants”).
Each of the Q1 2017 Inducement Grants has an exercise price per share equal to the closing price of the Company's common stock
on December 30, 2016, the last trading date prior to the date of grant. Each stock option has a 10 year term and vests over
four years, with 25% of the original number of shares underlying the award vesting on the first anniversary of the employee’s date
of hire and an additional 6.25% of the original number of shares underlying the award vesting on each successive three-month period
thereafter, subject to the new employee's continued service with the Company through the respective vesting dates. Each stock
option was granted as an inducement equity award outside of the Company's Amended and Restated 2010 Stock Incentive Plan, as
amended, and was made as an inducement material to such employee's acceptance of employment with the Company.
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates
for the treatment of human cancers, including its lead development candidate, CUDC-907 that is being investigated in clinical
studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the
areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small
molecule antagonists of the PD-1 and VISTA pathways, including PD-L1/VISTA antagonist CA-170, and oral small molecule antagonists
of the PD-1 and TIM-3 pathways, including PD-L1/TIM-3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4
kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors
and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche
are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other
diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis's website at www.curis.com.
Cautionary Note Regarding Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation statements regarding the potential advantages and benefits of small molecule checkpoint
inhibitors and Curis’s plans and expectations for the collaboration with Aurigene, including its plans to discover and
develop multiple first-in-class oral, small molecule checkpoint inhibitors for the treatment of patients with
cancer. Forward-looking statements may contain the words "believes," "expects," "anticipates," "plans," "seeks,"
"estimates," "assumes," "will," "may," "could" or similar expressions. These forward-looking statements are not guarantees of
future performance and involve risks, uncertainties, assumptions and other important factors that may cause actual results to be
materially different from those indicated by such forward-looking statements. For example, Curis may experience adverse
results, delays and/or failures in its drug development programs and may not be able to successfully advance the development of its
drug candidates in the time frames it projects, if at all. Curis's drug candidates may cause unexpected toxicities, fail to
demonstrate sufficient safety and efficacy in clinical studies and/or may never achieve the requisite regulatory approvals needed
for commercialization. Favorable results seen in preclinical studies and early clinical trials of Curis’s drug candidates may not
be replicated in later trials. There can be no guarantee that the collaboration agreement with Aurigene will continue for its
full term, that Curis or Aurigene will each maintain the financial and other resources necessary to continue financing its portion
of the research, development and commercialization costs, that the parties will successfully discover, develop or commercialize
drug candidates under the collaboration, or that Curis receive full or partial benefit of payments waived by
Aurigene. Curis Royalty may not receive sufficient levels of royalty revenue from sales of Erivedge to satisfy its
royalty-collateralized debt obligation or may otherwise lose its rights to Erivedge royalties and royalty-related payments as a
result of a foreclosure of the loan. Curis will require substantial additional capital to fund its business and such capital may
not be available on reasonable terms, or at all. Curis also faces risks relating to: potential adverse decisions made by the FDA
and other regulatory authorities, investigational review boards, and publication review bodies; competition; its ability to obtain
or maintain necessary patent protection; unstable market and economic conditions; unplanned expenses; and
other important risks relating to its business, operations, financial condition and future prospects that are discussed
in its most recent Form 10-K and Form 10-Q and other filings that it periodically makes with the Securities and Exchange
Commission.
In addition, any forward-looking statements represent the views of Curis only as of today and should not be relied upon as
representing Curis's views as of any subsequent date. Curis disclaims any intention or obligation to update any of the
forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise,
except as may be required by law.
For More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6500 jdentzer@curis.com Media Contact: David Schull Russo Partners 212-845-4271 david.schull@russopartnersllc.com
